Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

v3.25.2
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($)
Mar. 31, 2025
Mar. 31, 2024
Current assets:    
Cash $ 4,228,944 $ 3,589,244
VAT receivable 30,654 217,843
Inventories 94,675 60,383
Prepaid expenses and deposits 539,382 512,782
Total current assets 4,893,655 4,380,252
Non-current assets    
Right-of-use assets, net 306,652 206,090
Property, plant & equipment, net 1,226,596 897,627
Total non-current assets 1,533,248 1,103,717
Total assets 6,426,903 5,483,969
Current liabilities:    
Accounts payable and accrued liabilities 250,170 120,894
Current operating lease liabilities 52,993 47,955
Accounts payable - related parties 337,576  
Loan payable 32,468  
Total current liabilities 673,207 168,849
Non-current liabilities:    
Non-current operating lease liabilities 291,543 176,345
Total liabilities 964,750 345,194
Commitment and contingencies (Note 15)
Stockholders' equity    
Ordinary shares, $0.001 par value, 50,000,000 shares authorized; 4,341,956 and 2,573,903 issued and outstanding as of March 31, 2025 and 2024, respectively 4,342 2,574
Reserves 30,168,692 23,890,229
Accumulated deficit (24,589,244) (18,527,997)
Accumulated other income 112,330 1,951
Total stockholders' equity (Virax) 5,696,120 5,366,757
Non-controlling interests (233,967) (227,982)
Total stockholders' equity attributable to Virax Biolabs Group Limited ordinary shareholders 5,462,153 5,138,775
Total liabilities and stockholders' equity $ 6,426,903 $ 5,483,969